Innovations in process development and manufacturing for scaling ADCs

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Innovations in process development and manufacturing for scaling ADCs

Antibody–drug conjugates (ADCs) represent a rapidly expanding segment of targeted therapies, offering high specificity and potent anti-tumor activity. However, their complex structure and multi-step production make them especially challenging to scale from lab-scale synthesis to commercial-scale production.

As more ADCs move from clinical trials toward commercialization, the need for robust, scalable, and cost-efficient manufacturing strategies is more urgent than ever. Innovations in process optimization, automation, and scalable technologies are key to meeting this demand without compromising product quality or regulatory compliance.

In this webinar, Bioconjugation Insights will host a panel of experts who will explore the evolving landscape of ADC process development and manufacturing.

Attend this webinar to:

Understand emerging process innovations that support ADC scalability and quality
Learn how to overcome bottlenecks in conjugation and purification workflows
Gain insights into tech transfer, CMC strategies, and regulatory considerations for late-stage ADCs

Esohe Idusogie

Editorial Advisory Board Member at Bioconjugation Insights

Esohe has over 25 years of hands-on and management experience in the biopharmaceutical industry, supporting the development of biological products, including monoclonal antibodies and antibody-drug conjugates. She has led analytical teams and managed CMC projects from the preclinical stage through commercialization.

She has extensive experience in method development and validation, including bioanalytical and bioassay development, validation, and technology transfer. Esohe has established new analytical, bioassay, and bioanalytical laboratories and systems to support process development and assay transfer to GLP and GMP laboratories.

Additionally, she has selected, managed, and audited GMP and GLP contract testing laboratories in support of manufacturing, method validation, method transfer, QC release, and stability testing. Throughout her career, Esohe has authored and reviewed regulatory documents for multiple IND filings and late-phase programs, including BLA filings.

Juma Bridgewater

CMC Lead at Mythic Therapeutics

Dr Juma Bridgewater is an accomplished bioanalytical chemist with over 15 years of experience in the pharmaceutical and biotech industries. He is currently the Senior Director of CMC at Mythic Therapeutics where he leads the development and execution of analytical strategies for drug development and manufacturing.

He earned his PhD in Bioanalytical Chemistry from the University of Massachusetts Amherst, where he developed innovative methods for protein structure characterization and peptide sequencing.

With deep expertise in protein and small molecule characterization, control strategies, and CMC support, Dr. Bridgewater is recognized for his strategic leadership and impact on advancing therapeutics across multiple therapeutic areas.

Sunny Zhang

Senior Director Pharmaceutical Development at ADC Therapeutics

Sunny Zhang is a seasoned biopharmaceutical leader with over 20 years of expertise in CMC drug product development for biologics. She specializes in formulation, process development, tech transfer, and global regulatory strategy from early development through commercialization. Sunny has led high-impact programs across monoclonal antibodies, ADCs, and complex biologics, with proven success in CDMO management, IND/BLA submissions, and inspection readiness. A passionate and results-driven leader, she is committed to delivering innovative therapies that improve patient outcomes.

in 20

Days

You have registered for this webinar